病原生物学——高福

　　一、个人简介

　　高福，中国科学院院士、美国国家科学院外籍院士、美国医学科学院院士、英国皇家学会外籍院士、德国国家科学院院士、俄罗斯科学院外籍院士等。先后在山西农业大学（1979-1983）和北京农业大学（1983-1986）获得学士和硕士学位，1995年在英国牛津大学获得博士学位，相继在英国牛津大学，加拿大卡尔加里大学，美国哈佛大学/哈佛医学院从事博士后研究工作。2001-2004年在英国牛津大学任讲师、实验室主任、博士生导师，曾任中国科学院微生物研究所所长、中国疾病预防控制中心主任、国家自然科学基金委员会副主任。2004年入选中国科学院“百人计划”，2005年获得国家杰出青年基金资助。曾先后主持多项国家重大科研项目，“973”项目首席科学家，国家自然科学基金委员会“创新研究群体项目”负责人。在包括Cell, Nature, Science, Lancet, NEJM, NSMB, PNAS, Immunity等SCI国际刊物上发表论文。

　　二、主要研究方向

　　1、病原微生物跨宿主传播、感染机制与宿主细胞免疫、抗病毒手段等研究。

　　2、公共卫生政策与全球健康策略研究。

　　三、代表性论文、成果

　　1.Dai, L., Duan, H., Liu, X., Zhou, H., Duan, M., An, Y., Yuan, L., Zhao, X., Xu, K., Wu, Q. and Gao*, G. F., 2023, Omicron neutralisation from Delta-BA.1 RBD heterodimer booster or BF.7/BA.5.2 breakthrough infection. The Lancet, 28: 100613.

　　2.Li, D., Duan, M., Wang, X., Gao, P., Zhao, X., Xu*, K. and Gao, G. F., 2023, Neutralization of BQ.1, BQ.1.1, and XBB with RBD-dimer vaccines. The New England Journal of Medicine, 388 (12): 1142-1145.

　　3.Li, L., Liao, H., Meng, Y., Li, W., Han, P., Liu, K., Wang, Q., Li, D., Zhang, Y., Wang, L., Fan, Z., Zhang, Y., Wang, Q., Zhao*, X., Sun*, Y., Huang*, N., Qi*, J. and Gao*, G. F., 2022, Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1.. Cell, 185 (16): 2952-2960.e10.

　　4.Xu, K., Gao, P., Liu, S., Lu, S., Lei, W., Zheng, T., Liu, X., Xie, Y., Zhao, Z., Guo, S., Tang, C., Yang, Y., Yu, W., Wang, J., Zhou, Y., Huang, Q., Liu, C., An, Y., Zhang, R., Han, Y., Duan, M., Wang, S., Yang, C., Wu, C., Liu, X., She, G., Liu, Y., Zhao, X., Xu, K., Qi, J., Wu*, G., Peng*, X., Dai*, L., Wang*, P. and Gao*, G. F., 2022, Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell, 185 (13): 2265-2278.e14.

　　5.Han, P., Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, P., Li, X., Peng, Q., Su, C., Huang, B., Li, D., Zhang, R., Tian, M., Fu, L., Gao, Y., Zhao, X., Liu, K., Qi*, J., Gao*, G. F. and Wang*, P., 2022, Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell, 185 (4): 630-640.e10.

　　6.Sun, H., Li, H., Tong, Q., Han, Q., Liu, J., Yu, H., Song, H., Qi, J., Li, J., Yang, J., Lan, R., Deng, G., Chang, H., Qu, Y., Pu, J., Sun, Y., Lan, Y., Wang, D., Shi, Y., Liu, W. J., Chang, K. C., Gao*, G. F. and Liu*, J., 2023, Airborne transmission of human-isolated avian H3N8 influenza virus between ferrets. Cell, 186 (19): 4074-4084.e11.

　　7.Zhao, X., Zhang, R., Qiao, S., Wang, X., Zhang, W., Ruan, W., Dai, L., Han, P. and Gao*, G. F., 2022, Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. The New England Journal of Medicine, 387 (3): 277-280.

　　8.Wang, H., Yin, P., Zheng, T., Qin, L., Li, S., Han, P., Qu, X., Wen, J., Ding, H., Wu, J., Kong, T., Gao, Z., Hu, S., Zhao, X., Cao, X., Fang, M., Qi, J., Xi, JJ., Duan, K., Yang, X., Zhang, Z., Wang, Q., Tan, W., Gao*, G.F., 2024, Rational design of a 'two-in-one' immunogen DAM drives potent immune response against monkeypox virus. Nature Immunology, Jan 5. doi: 10.1038/s41590-023-01715-7. Online ahead of print.

　　9.Dai, L., Gao, L., Tao, L., Hadinegoro, S. R., Erkin, M., Ying, Z., He, P., Girsang, R. T., Vergara, H., Akram, J., Satari, H. I., Khaliq, T., Sughra, U., Celi, A. P., Li, F., Li, Y., Jiang, Z., Dalimova, D., Tuychiev, J., Turdikulova, S., Ikram, A., Lastra, N. F., Ding, F., Suhardono, M., Fadlyana, E., Yan, J., Hu, Z., Li, C., Abdurakhmonov, I. Y., Gao*, G. F. and ZF2001 Global Trial Group, 2022, Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. The New England Journal of Medicine, 386 (22): 2097-2111.

　　10.Shi, Y., Zhang, W., Wang, F., Qi, J., Wu, Y., Song, H., Gao, F., Bi, Y., Zhang, Y., Fan, Z., Qin, C., Sun, H., Liu, J., Haywood, J., Liu, W., Gong, W., Wang, D., Shu, Y., Wang, Y., Yan, J. and Gao*, G. F., 2013, Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science, 342 (6155): 243-247.